Gain insight into a uniquely structured company that aims to reduce the time, cost and risk of delivering drugs to market.
Streamlining drug development — at scale
Putting China's capital to work in the West
Japan: leading the way in regenerative medicine
Embedding digital into pharma's DNA
Augmenting R&D with artificial intelligence
Value-based healthcare and Value Labs
Life sciences dealmaking expected to continue
Australia’s diverted profits tax
Cracking the engaged aging code through technology
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Network brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
Pharmaceutical sector news
How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.